Skip to main content

Cross tolerance between LSD and psilocybin

Psychopharmacologia volume 2, pages 147–159 (1961)Cite this article

Summary

  1. 1.

    In two experiments, using a cross-over design, the development of “direct” tolerance to LSD and psilocybin was measured after 10 (Experiment I) or 9 (Experiment II) volunteers had taken LSD in doses increasing to 1.5 meg/kg over the course of 6–7 days (Experiment I) or 13 days (Experiment II). On another occasion, the same patients received psilocybin in doses increasing to 150 mcg/kg over the course of 6–7 days (Experiment I) or 210 mcg/kg over the course of 13 days (Experiment II).

  2. 2.

    The development of “cross” tolerance to psilocybin in patients “directly” tolerant to LSD was measured by “challenging” the patients, after they had received LSD chronically, with 150 mcg/kg (Experiment I) or 210 mcg/kg (Experiment II) of psilocybin. “Cross” tolerance to LSD was evaluated by “challenging” the patients, after they had received psilocybin chronically, with 1.5 meg/kg of LSD.

  3. 3.

    A high degree of “direct” tolerance to LSD developed in both experiments, as manifested by statistically significant reductions in six of the seven parameters of response. Patients “directly” tolerant to LSD were also “cross” tolerant to psilocybin on five (Experiment I) or four (Experiment II) parameters.

  4. 4.

    Definite “direct” tolerance also developed after chronic administration of psilocybin in both experiments, but statistically significant reductions occurred in fewer parameters of response (four in Experiment I and three in Experiment II) than was the case with LSD. Patients chronically treated with psilocybin were also “cross” tolerant to LSD on four (Experiment I) or three (Experiment II) measurements. The degree of “direct” tolerance to psilocybin was less than the degree of “direct” tolerance to LSD.

  5. 5.

    The development of “cross” tolerance between LSD and psilocybin reinforces the idea that these two drugs cause psychic disturbances by acting on some common mechanism, or on mechanisms acting through a common final pathway.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  • Balestrieri, A.: Studies on cross tolerance with LSD-25, UML-491 and JB-366. Psychopharmacologia 1, 257–259 (1960).

    Google Scholar 

  • Cerletti, A.: Étude pharmacologique de la psilocybine. Section 5, Chapter VII in R. Heim and R. G. Wasson, Les champignons hallucinogènes du Mexique. Paris: Editions du Muséum d'Histoire Naturelle 1958.

    Google Scholar 

  • Delay, J., P. Pichot, T. Lemperière, P. J. Nicolas-Charles, et A. M. Quétin: Étude psycho-physiologique et clinique de la psilocybine. Section 5, Chapter VII in R. Heim and R. G. Wasson, Les champignons hallucinogènes du Mexique. Paris: Editions du Muséum d'Histoire Naturelle 1958.

    Google Scholar 

  • Edwards, A. L.: Statistical analysis for students in psychology and education. New York. Rhinehart & Co. 1946.

    Google Scholar 

  • Hofman, A. R., R. Heim, A. Brack and H. Kobel: Psilocybin, ein psychotroper Wirkstoff an dem Mexikanischen Rauschpilz. Psilocybe Mexicana Heim. Experientia (Basel) 14, 107 (1958a).

    Google Scholar 

  • — and P. Troxler: Konstitutionsaufklärung und Synthese von Psilocybin. Experientia (Basel) 14, 397 (1958b).

    Google Scholar 

  • Isbell, H.: Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1, 29–38 (1959).

    Google Scholar 

  • Isbell, H., R. E. Belleville, H. F. Fraser, A. Wikler and C. R. Logan: Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch. Neurol. Psychiat. (Chicago) 76, 468–478 (1956).

    Google Scholar 

  • — and E. J. Miner: Studies on lysergic acid diethylamide (LSD-25). III. Attempts to attenuate the LSD-reaction in man by pretreatment with neurohumoral blocking agents. Arch. Neurol. Psychiat. (Chicago) 81, 20–27 (1959).

    Google Scholar 

  • Wasson, V. P., and R. G. Wasson: Mushrooms, Russia and history. New York: Pantheon Books 1957.

    Google Scholar 

  • Wilcoxon, F.: Some rapid approximate statistical procedures. New York: American Cyanamid Company 1949.

    Google Scholar 

  • Winter, C. A., and L. Flataker: Studies on heptazone (6-morpholino-4,4-diphenyl-3 heptanone hydrochloride) in comparison with other analgesic agents. J. Pharmacol. exp. Ther. 98, 305–317 (1950).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Mental Health Addiction Research Center, U.S. Public Health Service Hospital, Lexington, Kentucky

    Harris Isbell, A. B. Wolbach, A. Wikler & E. J. Miner

Authors
  1. Harris Isbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. B. Wolbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Wikler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. J. Miner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Isbell, H., Wolbach, A.B., Wikler, A. et al. Cross tolerance between LSD and psilocybin. Psychopharmacologia 2, 147–159 (1961). https://doi.org/10.1007/BF00407974

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00407974

Keywords

  • Common Mechanism
  • Chronic Administration
  • Common Final Pathway
  • Psilocybin
  • Final Pathway